We are a biotech company focusing on aging-related diseases. Specifically, we target diseases like a type of heart failure (HFpEF) and skin aging, which are caused by increased tissue stiffness. These are traditionally thought to be undruggable and irreversible, but we want to change that. We started building in June 2026, and recently completed the computation for designing our lead candidates.